We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-13.32%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.5B
AUM Growth
-$255M
Cap. Flow
+$290M
Cap. Flow %
11.6%
Top 10 Hldgs %
45.64%
Holding
89
New
6
Increased
32
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$50.9M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$35.6M
3
RLAY icon
Relay Therapeutics
RLAY
+$34M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$31.1M
5
ARGX icon
argenx
ARGX
+$29.1M

Top Sells

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$55.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$50.6M
3
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$29.4M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$6.95M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPRO icon
51
Spero Therapeutics
SPRO
$68.9M
$13.8M 0.55%
1,585,615
– –
SLN
52
Silence Therapeutics
SLN
$528M
$12.7M 0.51%
666,666
– –
PYXS icon
53
Pyxis Oncology
PYXS
$169M
$11.6M 0.46%
2,861,851
+1,070,500
+60% +$7.83M
COGT icon
54
Cogent Biosciences
COGT
$6.73B
$11.5M 0.46%
1,532,282
– –
CBIO
55
Crescent Biopharma
CBIO
$526M
$10.9M 0.44%
95,443
– –
NUVL
56
DELISTED
Nuvalent
NUVL
$9.58M 0.38%
689,418
+240,906
+54% +$3.5M
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$259M
$9.17M 0.37%
2,326,710
+948,690
+69% +$3.68M
VYGR icon
58
Voyager Therapeutics
VYGR
$184M
$9.06M 0.36%
1,189,100
+1,166,900
+5,256% +$5.21M
MOLN
59
Molecular Partners
MOLN
$8.98M 0.36%
443,221
– –
DAWN
60
DELISTED
Day One Biopharmaceuticals
DAWN
$8.03M 0.32%
809,282
– –
IVA
61
Inventiva
IVA
$1.04B
$7.94M 0.32%
686,040
+141,540
+26% +$1.72M
CNCE
62
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$7.59M 0.3%
2,253,000
– –
INFI
63
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.24M 0.29%
6,353,645
– –
ELEV
64
DELISTED
Elevation Oncology
ELEV
$5.83M 0.23%
2,312,198
+700,500
+43% +$2.81M
CDTX
65
DELISTED
Cidara Therapeutics
CDTX
$5.71M 0.23%
343,056
– –
GNCA
66
DELISTED
Genocea Biosciences, Inc.
GNCA
$5.02M 0.2%
4,012,404
– –
CALA
67
DELISTED
Calithera Biosciences, Inc
CALA
$3.75M 0.15%
464,746
+92,129
+25% +$941K
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
$3.34M 0.13%
+378,000
New +$2.87M
GLMD icon
69
Galmed Pharmaceuticals
GLMD
$4.96M
$2.86M 0.11%
9,998
– –
RNTX
70
Rein Therapeutics
RNTX
$63.3M
$2.7M 0.11%
263,278
– –
FWP
71
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.52M 0.1%
432,892
– –
PHXM
72
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$2.39M 0.1%
131,466
– –
ELTX icon
73
Elicio Therapeutics
ELTX
$74.1M
$2.27M 0.09%
107,130
– –
CRVS icon
74
Corvus Pharmaceuticals
CRVS
$1.1B
$2.25M 0.09%
1,370,947
– –
LITS
75
Lite Strategy Inc
LITS
$32.8M
$2.13M 0.09%
176,603
– –
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q1 2022 Portfolio in Review

As of Q1 2022, BVF Inc held 89 positions worth $2.5B, down 9.3% from $2.76B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

BVF Inc deployed $290M of net new capital in Q1 2022, opening 6 new positions and adding to 32 existing holdings. Its largest new stake was iTeos Therapeutics: 1,400,201 shares worth $45.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $50.6M trimmed.

  • BVF Inc's largest Q1 2022 buy was iTeos Therapeutics: 1,400,201 shares worth $45.1M.
  • BVF Inc added most to Relay Therapeutics in Q1 2022, an estimated $34M increase.
  • BVF Inc's biggest Q1 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $50.6M.
  • BVF Inc fully exited Amarin Corp in Q1 2022, selling an estimated $55.5M.
  • BVF Inc's ten largest holdings make up 46% of its $2.5B portfolio in Q1 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q1 2022.
  • BVF Inc's portfolio value fell 9.3% quarter-over-quarter to $2.5B.

Based on BVF Inc's 13F filing for Q1 2022, filed 16 May 2022.